Header Logo

Connection

CHARLES WYKOFF to Diabetic Retinopathy

Back to Details
This is a "connection" page, showing publications CHARLES WYKOFF has written about Diabetic Retinopathy.
CHARLES WYKOFF
Connection Strength
23.051
Diabetic Retinopathy
  1. Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials. Ophthalmology. 2024 Jun; 131(6):708-723.
    View in: PubMed
    Score: 0.721
  2. Subthreshold Compared with Threshold Macular Photocoagulation for Diabetic Macular Edema: A Systematic Review and Meta-Analysis. Ophthalmol Retina. 2024 Mar; 8(3):223-233.
    View in: PubMed
    Score: 0.709
  3. Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical Trial. JAMA Ophthalmol. 2023 09 01; 141(9):834-842.
    View in: PubMed
    Score: 0.705
  4. KESTREL and KITE Phase 3 Studies: 100-Week Results With Brolucizumab in Patients With Diabetic Macular Edema. Am J Ophthalmol. 2024 04; 260:70-83.
    View in: PubMed
    Score: 0.698
  5. Quantifying burden of intravitreal injections: questionnaire assessment of life impact of treatment by intravitreal injections (QUALITII). BMJ Open Ophthalmol. 2022 12; 7(1).
    View in: PubMed
    Score: 0.671
  6. Role of anti-vascular endothelial growth factor in the management of non-proliferative diabetic retinopathy without centre-involving diabetic macular oedema: a meta-analysis of trials. Eye (Lond). 2023 07; 37(10):1966-1974.
    View in: PubMed
    Score: 0.666
  7. Favorable Anti-VEGF Crunch Syndrome: Nonsurgical Relief of Vitreoretinal Traction in Eyes With Proliferative Diabetic Retinopathy and Tractional Retinal Detachment. Ophthalmic Surg Lasers Imaging Retina. 2022 08; 53(8):455-459.
    View in: PubMed
    Score: 0.654
  8. Frequency and timing of antivascular endothelial growth factor treatment for eyes with centre-involved diabetic macular oedema and good vision: Protocol V results in context. BMJ Open Ophthalmol. 2022 08; 7(1).
    View in: PubMed
    Score: 0.654
  9. Final Outcomes from the Randomized RECOVERY Trial of Aflibercept for Retinal Nonperfusion in Proliferative Diabetic Retinopathy. Ophthalmol Retina. 2022 07; 6(7):557-566.
    View in: PubMed
    Score: 0.635
  10. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022 02 19; 399(10326):741-755.
    View in: PubMed
    Score: 0.631
  11. Retinal non-perfusion in diabetic retinopathy. Eye (Lond). 2022 02; 36(2):249-256.
    View in: PubMed
    Score: 0.629
  12. Real-Time Photographic- and Fluorescein Angiographic-Guided Management of Diabetic Retinopathy: Randomized PRIME Trial Outcomes. Am J Ophthalmol. 2021 06; 226:126-136.
    View in: PubMed
    Score: 0.589
  13. Risk of Blindness Among Patients With Diabetes and Newly Diagnosed Diabetic Retinopathy. Diabetes Care. 2021 03; 44(3):748-756.
    View in: PubMed
    Score: 0.588
  14. Visual Acuity Variability: Comparing Discrepancies between Snellen and ETDRS Measurements among Subjects Entering Prospective Trials. Ophthalmol Retina. 2021 03; 5(3):224-233.
    View in: PubMed
    Score: 0.558
  15. Loss to Follow-Up Among Patients With Proliferative Diabetic Retinopathy in Clinical Practice. Am J Ophthalmol. 2020 07; 215:66-71.
    View in: PubMed
    Score: 0.555
  16. Protecting Vision in Patients With Diabetes With Ultra-Widefield Imaging: A Review of Current Literature. Ophthalmic Surg Lasers Imaging Retina. 2019 10 01; 50(10):639-648.
    View in: PubMed
    Score: 0.537
  17. Intravitreal Aflibercept for Retinal Nonperfusion in Proliferative Diabetic Retinopathy: Outcomes from the Randomized RECOVERY Trial. Ophthalmol Retina. 2019 12; 3(12):1076-1086.
    View in: PubMed
    Score: 0.530
  18. Thresholds for Initiating Treatment of Eyes with Diabetic Macular Edema and Good Vision: Consideration of DRCR.Net Protocol V Results. Ophthalmol Retina. 2019 11; 3(11):917-919.
    View in: PubMed
    Score: 0.530
  19. Longitudinal Retinal Perfusion Status in Eyes with Diabetic Macular Edema Receiving Intravitreal Aflibercept or Laser in VISTA?Study. Ophthalmology. 2019 08; 126(8):1171-1180.
    View in: PubMed
    Score: 0.519
  20. Suprachoroidal Space Alterations Following Delivery of Triamcinolone Acetonide: Post-Hoc Analysis of the Phase 1/2 HULK Study of Patients With Diabetic Macular Edema. Ophthalmic Surg Lasers Imaging Retina. 2018 09 01; 49(9):692-697.
    View in: PubMed
    Score: 0.498
  21. The Intersection of Diabetes Mellitus and Cataract Surgery: Current State of Management. Ophthalmol Retina. 2018 02; 2(2):83-85.
    View in: PubMed
    Score: 0.475
  22. Intravitreal aflibercept for proliferative diabetic retinopathy. Lancet. 2017 11 11; 390(10108):2141.
    View in: PubMed
    Score: 0.471
  23. Long-term outcomes with as-needed aflibercept in diabetic macular oedema: 2-year outcomes of the ENDURANCE extension study. Br J Ophthalmol. 2018 05; 102(5):631-636.
    View in: PubMed
    Score: 0.463
  24. Impact of intravitreal pharmacotherapies including antivascular endothelial growth factor and corticosteroid agents on diabetic retinopathy. Curr Opin Ophthalmol. 2017 May; 28(3):213-218.
    View in: PubMed
    Score: 0.454
  25. Long-term Effects of Intravitreal 0.19 mg Fluocinolone Acetonide Implant on Progression and Regression of Diabetic Retinopathy. Ophthalmology. 2017 04; 124(4):440-449.
    View in: PubMed
    Score: 0.445
  26. Outcomes With As-Needed Aflibercept and Macular Laser Following the Phase III VISTA DME Trial: ENDURANCE 12-Month Extension Study. Am J Ophthalmol. 2017 Jan; 173:56-63.
    View in: PubMed
    Score: 0.436
  27. Predictors of Diabetic Macular Edema Treatment Frequency with Ranibizumab During the Open-Label Extension of the RIDE and RISE Trials. Ophthalmology. 2016 08; 123(8):1716-1721.
    View in: PubMed
    Score: 0.425
  28. DRCR Protocol-T: Reconciling 1- and 2-Year Data for Managing Diabetic Macular Edema. Ophthalmic Surg Lasers Imaging Retina. 2016 Apr 01; 47(4):308-12.
    View in: PubMed
    Score: 0.421
  29. Comparing aflibercept, bevacizumab, and ranibizumab for DME: analysis of DRCR Protocol T. Ophthalmic Surg Lasers Imaging Retina. 2015 Mar; 46(3):302-5.
    View in: PubMed
    Score: 0.391
  30. Port Delivery System With Ranibizumab vs Monitoring in Nonproliferative Diabetic Retinopathy Without Macular Edema: The Pavilion Randomized Clinical Trial. JAMA Ophthalmol. 2025 Apr 01; 143(4):317-325.
    View in: PubMed
    Score: 0.197
  31. Spectral-domain OCT characteristics of intraretinal hyper-reflective foci associated with age-related macular degeneration and diabetic retinopathy. Can J Ophthalmol. 2025 Apr; 60(2):91-99.
    View in: PubMed
    Score: 0.188
  32. Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial. Lancet. 2024 03 23; 403(10432):1153-1163.
    View in: PubMed
    Score: 0.183
  33. Efficacy and Safety of Brolucizumab for Diabetic Macular Edema: The KINGFISHER Randomized Clinical Trial. JAMA Ophthalmol. 2023 12 01; 141(12):1152-1160.
    View in: PubMed
    Score: 0.179
  34. Longitudinal Quantitative Ultrawidefield Angiographic Features in Diabetic Retinopathy Treated with Aflibercept from the Intravitreal Aflibercept as Indicated by Real-Time Objective Imaging to Achieve Diabetic Retinopathy Improvement Trial. Ophthalmol Retina. 2024 Feb; 8(2):116-125.
    View in: PubMed
    Score: 0.176
  35. Anti-vascular endothelial growth factor therapy and retinal non-perfusion in diabetic retinopathy: A meta-analysis of randomised trials. Acta Ophthalmol. 2024 Feb; 102(1):e31-e41.
    View in: PubMed
    Score: 0.171
  36. Archway Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration 2-Year Results. Ophthalmology. 2023 Jul; 130(7):735-747.
    View in: PubMed
    Score: 0.170
  37. Association of Predominantly Peripheral Lesions on Ultra-Widefield Imaging and the Risk of Diabetic Retinopathy Worsening Over Time. JAMA Ophthalmol. 2022 10 01; 140(10):946-954.
    View in: PubMed
    Score: 0.165
  38. Association of Ultra-Widefield Fluorescein Angiography-Identified Retinal Nonperfusion and the Risk of Diabetic Retinopathy Worsening Over Time. JAMA Ophthalmol. 2022 10 01; 140(10):936-945.
    View in: PubMed
    Score: 0.165
  39. Treat-and-extend versus alternate dosing strategies with anti-vascular endothelial growth factor agents to treat center involving diabetic macular edema: A systematic review and meta-analysis of 2,346 eyes. Surv Ophthalmol. 2022 Sep-Oct; 67(5):1346-1363.
    View in: PubMed
    Score: 0.160
  40. Baseline retinal vascular bed area on ultra-wide field fluorescein angiography correlates with the anatomical outcome of diabetic macular oedema to ranibizumab therapy: two-year analysis of the DAVE Study. Eye (Lond). 2023 03; 37(4):678-683.
    View in: PubMed
    Score: 0.159
  41. NEW BIOMARKER QUANTIFYING THE EFFECT OF ANTI-VEGF THERAPY IN EYES WITH PROLIFERATIVE DIABETIC RETINOPATHY ON ULTRAWIDE FIELD FLUORESCEIN ANGIOGRAPHY: RECOVERY Study. Retina. 2022 03 01; 42(3):426-433.
    View in: PubMed
    Score: 0.159
  42. Treat-and-extend regimens of anti-vascular endothelial growth factor therapy for retinal vein occlusions: a systematic review and meta-analysis. Acta Ophthalmol. 2022 Sep; 100(6):e1199-e1208.
    View in: PubMed
    Score: 0.156
  43. Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial. JAMA Ophthalmol. 2021 Sep 01; 139(9):946-955.
    View in: PubMed
    Score: 0.153
  44. Deep learning-enabled ultra-widefield retinal vessel segmentation with an automated quality-optimized angiographic phase selection tool. Eye (Lond). 2022 09; 36(9):1783-1788.
    View in: PubMed
    Score: 0.153
  45. Exploring the angiographic-biologic phenotype in the IMAGINE study: quantitative UWFA and cytokine expression. Br J Ophthalmol. 2022 10; 106(10):1444-1449.
    View in: PubMed
    Score: 0.151
  46. Retinal vascular bed area on ultra-wide field fluorescein angiography indicates the severity of diabetic retinopathy. Br J Ophthalmol. 2022 08; 106(8):1126-1131.
    View in: PubMed
    Score: 0.149
  47. RETINAL LEAKAGE INDEX DYNAMICS ON ULTRA-WIDEFIELD FLUORESCEIN ANGIOGRAPHY IN EYES TREATED WITH INTRAVITREAL AFLIBERCEPT FOR PROLIFERATIVE DIABETIC RETINOPATHY IN THE RECOVERY STUDY. Retina. 2020 Nov; 40(11):2175-2183.
    View in: PubMed
    Score: 0.145
  48. Effects of Long-Term DME Control With 0.2 ?g/Day Fluocinolone Acetonide Implant on Quality of Life: An Exploratory Analysis From the FAME Trial. Ophthalmic Surg Lasers Imaging Retina. 2020 11 01; 51(11):658-667.
    View in: PubMed
    Score: 0.145
  49. Automated vessel density detection in fluorescein angiography images correlates with vision in proliferative diabetic retinopathy. PLoS One. 2020; 15(9):e0238958.
    View in: PubMed
    Score: 0.143
  50. Aqueous Cytokine Expression and Higher Order OCT Biomarkers: Assessment of the Anatomic-Biologic Bridge in the IMAGINE DME Study. Am J Ophthalmol. 2021 02; 222:328-339.
    View in: PubMed
    Score: 0.143
  51. Effect of Aflibercept on Diabetic Retinopathy Severity and Visual Function in the RECOVERY Study for Proliferative Diabetic Retinopathy. Ophthalmol Retina. 2021 05; 5(5):409-419.
    View in: PubMed
    Score: 0.143
  52. Longitudinal panretinal microaneurysm dynamics on ultra-widefield fluorescein angiography in eyes treated with intravitreal aflibercept for proliferative diabetic retinopathy in the recovery study. Br J Ophthalmol. 2021 08; 105(8):1111-1115.
    View in: PubMed
    Score: 0.143
  53. Suprachoroidal CLS-TA plus Intravitreal Aflibercept for Diabetic Macular Edema: A Randomized, Double-Masked, Parallel-Design, Controlled Study. Ophthalmol Retina. 2021 01; 5(1):60-70.
    View in: PubMed
    Score: 0.143
  54. Association of Intravitreal Aflibercept With Optical Coherence Tomography Angiography Vessel Density in Patients With Proliferative Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial. JAMA Ophthalmol. 2020 08 01; 138(8):851-857.
    View in: PubMed
    Score: 0.142
  55. SEVERITY OF DIABETIC MACULAR EDEMA CORRELATES WITH RETINAL VASCULAR BED AREA ON ULTRA-WIDE FIELD FLUORESCEIN ANGIOGRAPHY: DAVE Study. Retina. 2020 Jun; 40(6):1029-1037.
    View in: PubMed
    Score: 0.141
  56. Long-term outcomes of treat-and-extend ranibizumab with and without navigated laser for diabetic macular oedema: TREX-DME 3-year results. Br J Ophthalmol. 2021 02; 105(2):253-257.
    View in: PubMed
    Score: 0.139
  57. Assessment of the DRCR Retina Network Approach to Management With Initial Observation for Eyes With Center-Involved Diabetic Macular Edema and Good Visual Acuity: A Secondary Analysis of a Randomized Clinical Trial. JAMA Ophthalmol. 2020 04 01; 138(4):341-349.
    View in: PubMed
    Score: 0.139
  58. Relationship Between Retinal Fractal Dimension and Nonperfusion in Diabetic Retinopathy on Ultrawide-Field Fluorescein Angiography. Am J Ophthalmol. 2020 01; 209:99-106.
    View in: PubMed
    Score: 0.133
  59. Relationship between duration and extent of oedema and visual acuity outcome with ranibizumab in diabetic macular oedema: A post hoc analysis of Protocol I data. Eye (Lond). 2020 03; 34(3):480-490.
    View in: PubMed
    Score: 0.132
  60. Distribution of Nonperfusion and Neovascularization on Ultrawide-Field Fluorescein Angiography in Proliferative Diabetic Retinopathy (RECOVERY Study): Report 1. Am J Ophthalmol. 2019 10; 206:154-160.
    View in: PubMed
    Score: 0.131
  61. Intravitreal Fluocinolone Acetonide May Decelerate Diabetic Retinal Neurodegeneration. Invest Ophthalmol Vis Sci. 2019 05 01; 60(6):2134-2139.
    View in: PubMed
    Score: 0.130
  62. Classification of Regions of Nonperfusion on Ultra-widefield Fluorescein Angiography in Patients with Diabetic Macular Edema. Am J Ophthalmol. 2019 10; 206:74-81.
    View in: PubMed
    Score: 0.130
  63. Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial. Ophthalmology. 2019 08; 126(8):1155-1170.
    View in: PubMed
    Score: 0.129
  64. Randomized Trial of Treat and Extend Ranibizumab With and Without Navigated Laser Versus Monthly Dosing for Diabetic Macular Edema: TREX-DME 2-Year Outcomes. Am J Ophthalmol. 2019 06; 202:91-99.
    View in: PubMed
    Score: 0.129
  65. Comparison of Early Treatment Diabetic Retinopathy Study Standard 7-Field Imaging With Ultrawide-Field Imaging for Determining Severity of Diabetic Retinopathy. JAMA Ophthalmol. 2019 01 01; 137(1):65-73.
    View in: PubMed
    Score: 0.127
  66. When and How to Incorporate Steroids for Persistent Diabetic Macular Edema: A Discussion of Real-World Treatment Optimization Strategies. Ophthalmic Surg Lasers Imaging Retina. 2018 07 01; 49(7):S5-S15.
    View in: PubMed
    Score: 0.123
  67. Retinopathy Regression with Treat and Extend Ranibizumab for Diabetic Macular Edema. Ophthalmology. 2018 08; 125(8):1304-1306.
    View in: PubMed
    Score: 0.122
  68. Identification of factors to increase efficacy of telemedicine screening for diabetic retinopathy in endocrinology practices using the Intelligent Retinal Imaging System (IRIS) platform. Diabetes Res Clin Pract. 2018 Jun; 140:265-270.
    View in: PubMed
    Score: 0.121
  69. Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema. Ophthalmology. 2018 07; 125(7):1054-1063.
    View in: PubMed
    Score: 0.120
  70. Targeted Retinal Photocoagulation for Diabetic Macular Edema with Peripheral Retinal Nonperfusion: Three-Year Randomized DAVE Trial. Ophthalmology. 2018 05; 125(5):683-690.
    View in: PubMed
    Score: 0.119
  71. Distribution of Nonperfusion Area on Ultra-widefield Fluorescein Angiography in Eyes With Diabetic Macular Edema: DAVE Study. Am J Ophthalmol. 2017 Aug; 180:110-116.
    View in: PubMed
    Score: 0.114
  72. Relationship Between Visual Acuity and Retinal Thickness During Anti-Vascular Endothelial Growth Factor Therapy for Retinal Diseases. Am J Ophthalmol. 2017 Aug; 180:8-17.
    View in: PubMed
    Score: 0.114
  73. Randomized Trial of Treat and Extend Ranibizumab with and without Navigated Laser for Diabetic Macular Edema: TREX-DME 1 Year Outcomes. Ophthalmology. 2017 01; 124(1):74-81.
    View in: PubMed
    Score: 0.110
  74. Regulatory Factors Influencing Usage of Retinal Pharmaceuticals: A Look Both Home and Abroad. Am J Ophthalmol. 2016 09; 169:xiv-xvi.
    View in: PubMed
    Score: 0.108
  75. ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION: Role of Prophylactic Topical Ophthalmic Antibiotics. Retina. 2016 Jul; 36(7):1349-56.
    View in: PubMed
    Score: 0.107
  76. Not All Retina Is Created Equal: Metabolic Quantification of Ultra-Widefield Images. Ophthalmology. 2015 Dec; 122(12):2580-2.
    View in: PubMed
    Score: 0.100
  77. Neutralization of vascular endothelial growth factor slows progression of retinal nonperfusion in patients with diabetic macular edema. Ophthalmology. 2014 Sep; 121(9):1783-9.
    View in: PubMed
    Score: 0.092
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.